Lite Strategy

Lite Strategy Equity Ratio

The Equity Ratio of Lite Strategy (LITS) as of Nov 20, 2026 is 97.50 %. In the previous year, Equity Ratio was 92.60 % — a change of 5.29% (higher).

Equity Ratio

97.50 %

YoY

5.29%

Last updated:

Equity Ratio of Lite Strategy is 2026 97.50 % . Equity Ratio of Lite Strategy was 2025 92.60 % . It decreases by 5.29% higher compared to the previous year.

The Lite Strategy Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2019
57.92 USD
Jan 1, 2020
36.77 USD
Jan 1, 2021
28.41 USD
Jan 1, 2022
29.47 USD
Jan 1, 2023
20.38 USD
Jan 1, 2024
79.81 USD
Jan 1, 2025
92.60 USD
Jan 1, 2026
97.50 USD
The Lite Strategy Equity Ratio history
YEAREquity RatioYoY
97.50 %+5.29%
92.60 %+16.02%
79.81 %+291.54%
20.38 %-30.84%
29.47 %+3.73%
28.41 %-22.72%
36.77 %-36.52%
57.92 %+20.08%
48.23 %-47.11%
91.20 %+3.23%
88.35 %-4.27%
92.28 %+1.68%
90.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lite Strategy Stock analysis

What does Lite Strategy do? MEI Pharma, Inc. develops cancer therapies, focusing on clinical drug candidates including Pracinostat, ME-344, and ME-401. Pracinostat, an HDAC inhibitor for hematologic diseases like AML and MDS, has undergone Phase I and II trials. ME-344 targets mitochondrial components in rapidly proliferating cells, while ME-401 inhibits PI3K delta for hematologic cancer treatment. The company generates revenue through clinical development and potential future drug sales, targeting oncology markets with its pipeline of cancer therapies. The firm's products are developed for specific cancer indications, with Pracinostat tested in advanced hematologic malignancies and solid tumors. ME-344 and ME-401 address unmet needs in mitochondrial and PI3K delta pathways, respectively. MEI Pharma's revenue model relies on clinical trial progress and future commercialization of these therapies, aiming to secure partnerships or direct sales in oncology. MEI Pharma's portfolio includes three clinical drug candidates, each targeting distinct cancer mechanisms. Pracinostat is advanced in trials for AML and MDS, while ME-344 and ME-401 are in development for broader cancer applications. The company monetizes through potential drug approvals and sales, with a focus on hematologic cancers and solid tumor markets. Lite Strategy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lite Strategy stock

Equity Ratio of Lite Strategy is 97.50 % in 2026.

Equity Ratio of Lite Strategy changed from 92.60 % to 97.50 %, representing a 5.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Lite Strategy since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Lite Strategy with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Lite Strategy

All Key Metrics — Lite Strategy